215 Church Street
New Haven, CT 06510
Biohaven is a clinical-stage biopharmaceutical company with proven leadership from industry and academic settings…a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders…and strong support from top-tier biopharma investors.
We’re using a flat and highly entrepreneurial organizational structure – and deep experience in drug development – to leverage a range of intellectual property licensed from companies and institutions that include Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital.
Since our establishment in 2013, and especially since our initial public offering in 2017, we have made rapid progress with multiple compounds across our CGRP receptor antagonist and glutamate modulator platforms. Today, we are ready to achieve a number of new clinical and regulatory milestones , including an NDA filing for rimegepant — our novel, orally-dosed migraine treatment –in 2019, and an NDA filing for BHV-0223, our novel, sublingual formulation of riluzole for patients with ALS in the second half of 2018.